论文部分内容阅读
目的观察乙胺碘呋酮治疗急性心肌梗死后恶性心律失常的疗效及安全性。方法急性心肌梗死后恶性心律失常患者30例,给予乙胺碘呋酮负荷剂量75～150mg/次,15～20min静脉注射后以0.5～1.0mg/min速度微量泵维持静脉注射,观察用药后15min及1,2,24h心率、平均动脉压变化及疗效、不良反应发生情况。结果显效20例,有效8例,无效2例,总有效率93.3%;用药后各时间点平均动脉压、心率与用药前比较差异有统计学意义(P<0.05);用药期间患者均未出现QT间期明显延长、心功能恶化、室性心律失常加重或猝死;2例出现心动过缓者药物减量后心率恢复正常。结论乙胺碘呋酮治疗急性心肌梗死并恶性心律失常安全、有效,不良反应轻。
Objective To observe the efficacy and safety of amiodarone in the treatment of malignant arrhythmia after acute myocardial infarction. Methods Thirty patients with malignant arrhythmia after acute myocardial infarction were given amiodarone loading dose of 75-150mg / times. After intravenous injection of 15-20min, intravenous injection of 0.5-1.0mg / min micro-pump was used. After 15min And 1,2,24 h heart rate, mean arterial pressure changes and efficacy, adverse reactions. The results were markedly effective in 20 cases, effective in 8 cases and ineffective in 2 cases, with a total effective rate of 93.3%. Mean arterial pressure and heart rate at each time point after treatment were significantly different from those before treatment (P <0.05) QT interval was significantly prolonged cardiac dysfunction, ventricular arrhythmia or sudden death; 2 cases of patients with bradycardia heart rate reduction after regaining normal. Conclusion Amifostine is safe and effective in the treatment of acute myocardial infarction with malignant arrhythmia and has mild adverse reactions.